Angiopoietin-2 and VEGF-A Antagonist Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with abnormal angiogenesis, such as cancer, lack effective methods to inhibit the biological activities of Angiopoietin-2 and VEGF-A, and their receptors, leading to uncontrolled blood vessel formation and tumor growth.
Innovation Solution
A combination of an antagonist of Angiopoietin-2 and an antagonist of VEGF-A, or its receptors KDR and Flt1, using antibodies or tyrosine kinase inhibitors, specifically designed to inhibit the binding of Angiopoietin-2 to Tie-2 and VEGF-A to their receptors, thereby blocking angiogenic signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diseases associated with abnormal angiogenesis are used, then tumor growth and vascularization are not effectively controlled, but using a combination of Angiopoietin-2 antagonist and VEGF-A antagonist provides effective inhibition of angiogenesis
Solution Approach 1:
The patent combines two separate therapeutic agents (Angiopoietin-2 antagonist and VEGF-A antagonist) into a single treatment regimen. This merging of multiple mechanisms of action into one combination therapy achieves synergistic anti-angiogenic effects, effectively controlling tumor growth and vascularization while maintaining a practical treatment approach
2Productivity
If angiogenic factors and their receptors are not targeted, then blood vessel formation and tumor growth proceed uncontrolled, but targeting these factors requires specific antagonist compounds
Solution Approach 1:
The patent employs antagonist compounds as intermediary substances that specifically bind to and block the interaction between angiogenic factors (Angiopoietin-2, VEGF-A) and their receptors (Tie-2, KDR, Flt1). These intermediary antagonists prevent the pro-angiogenic signaling without requiring direct manipulation of the receptor structures themselves, enabling effective tumor growth control through available small molecule or protein-based antagonists
Data Source
Figure 1a
Figure 1b
Figure 2a
AI summary
The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.